N/A N=339 Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Rebleeding Rate — 97 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding
Gastro Intestinal Bleeding · Hematemesis · Melena
Primary: Rate of Detection of Bleeding — 11; 11 Participants
N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
N/A N=4 Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
N/A N=87 Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding
Melena · Gastrointestinal Hemorrhage
Primary: Time to Localization of Bleeding — 21; 16 hours — p=.002
N/A N=131 PillSense System for Detecting UGI Bleed
UGI Bleed · Upper Gastrointestinal Bleeding · Upper Gastrointestinal Bleed
Primary: Sensitivity — 26 Participants
N/A N=193 The Clinical Utility of Overtube Use at the Time of Endoscopy
Small Bowel Visualization
Primary: Number of Patients With Persistent or Recurrent Bleeding — 16 participants
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 2 N=55 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
N/A N=30 Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]
Upper GI Bleeding
Primary: Number of Participants With (Serious) Adverse Event Related to the Medical Device — 0 Participants
N/A N=162 Comparing Early Versus Elective Colonoscopy
Acute Lower Gastrointestinal Bleeding
Primary: Stigmata of Recent Hemorrhage (SRH) Identification Rate — 17; 17 Participants
N/A N=80 The Second-Generation MCCG for Upper Gastrointestinal Tract.
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=804 Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon
Colon Cancer
Primary: Total Number of Serrated Lesions Proximal to the Sigmoid Colon — 204; 158; 95; 59 Serrated Lesions
N/A N=341 Anticoagulation With Enhanced Gastrointestinal Safety
Upper Gastrointestinal Bleeding · Peptic Ulcer Hemorrhage · Anticoagulant-induced Bleeding
Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
Phase 1 N=10 Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)
Gastrointestinal Bleeding
Primary: Number of Participants With Side-Effects — 10 participants
N/A N=22 Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
Barrett's Esophagus
Primary: Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies. — 22 Participants
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
N/A N=21 EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
Obesity · Non-Alcoholic Steatohepatitis
Primary: Weight Loss Achieved With Intragastric Balloon (IGB) — 17 Participants
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Phase 1 N=23 Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
N/A N=42 Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 4 N=166 Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers
Bleeding Peptic Ulcer
Primary: Number of Participants With Rebleeding — 3; 4 Participants
N/A N=220 Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
Atrial Fibrillation
Primary: Percentage of Patients With Index Event Safety Outcomes (Ongoing/Resolved/Deceased) at Time of Hospital Discharge — 19.1; 76.8; 4.1 Percentage of participants
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL